Dicerna Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

2/4/19

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 419,000 shares of common stock to be distributed among 14 new employees with a grant date of February 1, 2019.

The stock options approved under the Inducement Grant were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $10.54, the fair market value on the grant date. The stock options vest over four years, with 25% vesting on the one-year anniversary of the employees’ first days of employment with the Company and 1/36 of the remaining shares vesting monthly thereafter, subject to the new employees’ continued service relationship with the Company on each such date. The stock options have a 10-year term and are subject to the terms and conditions of the applicable stock option agreement.

The Company granted the stock options as inducement materials to 14 new employees entering into employment with Dicerna Pharmaceuticals, Inc. in accordance with NASDAQ listing Rule 5635(c)(4).

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop, and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Boehringer Ingelheim, Eli Lilly and Company, and Alexion Pharmaceuticals. For more information, please visit www.dicerna.com.